treatment
experi
therefor
undertaken
attempt
demonstr
ribavirin
efficaci
experiment
infect
induc
two
wide
differ
virus
caus
hepat
laboratori
anim
result
experi
describ
report
virus
use
studi
rna
coronaviru
friendbraunstein
strain
murin
hepatitiss
mhv
obtain
american
type
cultur
collect
rockvil
md
dna
herpesviru
equin
abort
v
rs
eav
provid
dr
p
e
came
schere
corp
bloomfield
nj
virus
prepar
liver
homogen
two
intraperiton
ip
passag
pertin
host
anim
ribavirin
synthes
use
steril
physiolog
salin
solut
male
swiss
webster
mice
hilltop
lab
anim
inc
chatsworth
calif
weigh
g
femal
syrian
golden
hamster
lakeview
hamster
coloni
newfield
nj
weigh
g
use
studi
mhv
eav
respect
individu
cage
hamster
inocul
ip
approxim
time
lethal
dose
ld
eav
ribavirin
salin
administ
ip
hr
viru
inocul
continu
twice
daili
day
anim
observ
daili
death
two
dosag
drug
mgkgday
use
experi
later
repeat
use
mgkgday
anoth
experi
singl
ip
inject
mgkg
ribavirin
given
within
min
viru
inocul
ten
infect
hamster
use
group
receiv
ribavirin
infect
anim
receiv
salin
viru
control
five
uninfect
hamster
similarli
treat
serv
toxic
control
mice
inocul
ip
approxim
ld
mhv
seri
experi
first
studi
ribavirin
dose
mgkgday
administ
ip
anim
twice
daili
day
begin
hr
viru
inocul
experi
later
repeat
use
drug
dosag
mgkgday
eav
studi
ten
infect
anim
use
drug
treatment
group
use
viru
control
five
toxic
control
group
friend
et
report
mhvinfect
mice
viru
replic
result
liver
necrosi
increas
serum
glutam
oxaloacet
transaminas
sgot
experi
therefor
run
determin
effect
ribavirin
treatment
paramet
well
serum
bilirubin
concentr
viru
recover
liver
observ
necrosi
caus
infect
liver
experi
larg
group
mice
treat
ip
salin
ribavirin
rngkgday
twice
daili
day
begin
hr
viru
inocul
day
five
mice
per
group
remov
collect
blood
liver
sgot
activ
determin
colorimetr
use
kit
commerci
avail
sigma
chemic
co
st
loui
mo
serum
bilirubin
direct
likewis
measur
use
modifi
nosslin
employ
american
monitor
corp
reagent
indianapoli
ind
viru
level
liver
determin
use
death
endpoint
hamster
inject
ip
vari
dilut
liver
homogen
hamster
infect
eav
treat
salin
began
die
day
day
die
mean
surviv
time
day
figur
ribavirin
dosag
mgkgday
caus
increas
mean
surviv
time
day
statist
signific
p
ttest
ribavirintr
hamster
surviv
infect
toxic
seen
dose
lower
ribavirin
dosag
mgkgday
effect
experi
repeat
use
higher
ribavirin
level
mgkgday
dosag
lethal
toxic
control
anim
mgkgday
dosag
approxim
lethal
toxic
dose
caus
signific
p
increas
mean
surviv
time
infect
anim
ribavirin
administ
singl
ip
inject
time
viru
inocul
iday
increas
mean
surviv
time
seen
increas
insignific
ribavirin
three
higher
level
effect
prevent
death
mice
tabl
experi
repeat
use
alter
dose
signific
anti
viral
effect
seen
although
two
lowest
dose
effect
form
signific
mean
surviv
time
increas
tabl
viru
control
scot
level
rose
high
level
day
remain
elev
day
figur
day
mani
anim
die
continu
take
sampl
ribavirin
treatment
delay
increas
enzym
although
day
moder
increas
occur
later
studi
indic
level
soon
declin
normal
valu
toxic
control
anim
exhibit
signific
alter
scot
serum
bilirubin
level
likewis
elev
viru
control
anim
last
day
studi
figur
ribavirin
treatment
infect
uninfect
mice
caus
initi
moder
rise
bilirubin
declin
day
although
infect
treat
mice
rise
seen
day
concentr
mhv
liver
viru
control
mice
rel
high
level
day
increas
peak
concentr
day
drop
day
figur
latter
declin
may
result
select
process
sinc
major
anim
die
day
remain
aliv
may
lesser
initi
infect
maximum
viru
level
attain
preced
mean
day
death
day
ribavirin
treatment
markedli
slow
product
recover
viru
although
rel
high
titer
seen
day
day
mark
damag
plainli
visibl
viru
control
liver
infect
notabl
less
appar
ribavirintr
anim
score
appli
degre
liver
damag
mice
summar
tabl
liver
sampl
infect
untreat
mice
examin
histopatholog
found
moder
hepatosi
evidenc
cytoplasm
vacuol
form
cloudi
swell
lipidosi
focal
necrosi
hemorrhag
also
evid
studi
offer
consider
evid
parenter
administ
ribavirin
mark
effect
hepat
mice
induc
mhv
rna
viru
drug
least
treatment
regimen
use
experi
margin
influenc
hepat
hamster
induc
eav
dna
viru
preliminari
result
suggest
ketoaldehyd
deriv
steroid
c
pu
n
certain
substitut
morpholinium
quaternari
may
moder
efficaci
mhv
infect
drug
show
action
afainst
mhv
infect
includ
antihistamin
drug
benadryl
antibiot
streptothricin
studi
antihistamin
effect
prevent
necrosi
liver
cell
rather
inhibit
viral
replic
streptothricin
thought
exert
effect
direct
action
viru
therapeut
effect
action
ribavirin
indic
probabl
therapeut
antivir
effect
although
addit
studi
use
later
initi
treatment
need
drug
report
effect
eav
infect
hamster
includ
monophosphatelb
mhv
eav
infect
rapidli
fulmin
lethal
endpoint
infect
mimic
slowli
progress
less
fatal
human
hepat
infect
difficult
ascertain
predict
either
system
human
situat
score
assign
visual
examin
degre
damag
normal
liver
total
involv
liver
biochem
studi
indic
ribavirin
may
exert
antivir
effect
inhibit
enzym
involv
guanosin
monophosph
drug
readili
convert
liver
spleen
presum
adenosin
kinas
activ
involv
liver
spleen
drug
metabol
suggest
possibl
util
therapi
hepat
sinc
organ
primari
import
earli
replic
murin
hepat
virus
report
evid
ribavirin
inhibit
structur
nonstructur
polypeptid
antigen
influenza
viru
may
altern
mechan
action
drug
mhv
well
present
ribavirin
undergo
clinic
trial
acut
type
b
hepat
also
use
attempt
elimin
australian
antigen
posit
chronic
human
carrier
earli
report
suggest
definit
efficaci
type
infect
az
possibl
success
antigen
td
e
